Guillain-barré syndrome
Guillain-Barré syndrome is the most common cause of acute flaccid paralysis worldwide.
Most patients present with an antecedent illness, most commonly upper respiratory tract …
Most patients present with an antecedent illness, most commonly upper respiratory tract …
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
F Martins, L Sofiya, GP Sykiotis, F Lamine… - Nature reviews Clinical …, 2019 - nature.com
Abstract Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4
(CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 …
(CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 …
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update
BJ Schneider, J Naidoo, BD Santomasso… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated …
recommended management of immune-related adverse events (irAEs) in patients treated …
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice …
JR Brahmer, C Lacchetti, BJ Schneider… - Journal of Clinical …, 2018 - ascopubs.org
Purpose To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events in patients treated with …
recommended management of immune-related adverse events in patients treated with …
Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology
JA Thompson, BJ Schneider, J Brahmer… - Journal of the National …, 2019 - jnccn.org
The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to
provide guidance on the management of immune-related adverse events resulting from …
provide guidance on the management of immune-related adverse events resulting from …
Tissue-resident memory T cells populate the human brain
J Smolders, KM Heutinck, NL Fransen… - Nature …, 2018 - nature.com
Most tissues are populated by tissue-resident memory T cells (TRM cells), which are
adapted to their niche and appear to be indispensable for local protection against …
adapted to their niche and appear to be indispensable for local protection against …
Neurologic adverse events of immune checkpoint inhibitors: a systematic review
A Marini, A Bernardini, GL Gigli, M Valente… - Neurology, 2021 - AAN Enterprises
Objective To define the clinical characteristics, management, and outcome of neurologic
immune-related adverse events (n-irAEs) of immune checkpoint inhibitors (ICIs). Methods …
immune-related adverse events (n-irAEs) of immune checkpoint inhibitors (ICIs). Methods …
Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer
M Touat, T Maisonobe, S Knauss, O Ben Hadj Salem… - Neurology, 2018 - AAN Enterprises
Objective To report the clinicopathologic features and outcome of myositis in patients treated
with immune checkpoint inhibitors (ICIs)(irMyositis). Methods We retrospectively analyzed …
with immune checkpoint inhibitors (ICIs)(irMyositis). Methods We retrospectively analyzed …
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
M Kostine, A Finckh, CO Bingham, K Visser… - Annals of the …, 2021 - ard.bmj.com
Background Rheumatic and musculoskeletal immune-related adverse events (irAEs) are
observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given …
observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given …
Glial fibrillary acidic protein autoimmunity: a French cohort study
A Gravier-Dumonceau, R Ameli, V Rogemond, A Ruiz… - Neurology, 2022 - AAN Enterprises
Background and Objectives To report the clinical, biological, and imaging features and
clinical course of a French cohort of patients with glial fibrillary acidic protein (GFAP) …
clinical course of a French cohort of patients with glial fibrillary acidic protein (GFAP) …